Drug Profile
Research programme: neural thread protein based drugs - Nymox
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Nymox Pharmaceutical Corporation
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Neurological disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Neurological-disorders in Canada
- 04 Jun 2013 Development is ongoing in Canada
- 07 Oct 2003 Preclinical trials in Neurological disorders in USA (unspecified route)